Increasing Access to ctDNA Assessment for Biomarker Discovery, Development, & CDx Programs
Time: 12:45 pm
day: Day Two Track A
Details:
- A disruptive, low-cost approach to MRD detection and quantification using WGS and a proprietary dPCR platform
- Structural Variants (SVs) are the ideal pan-cancer biomarker for determining MRD status using dPCR
- Increased analytical sensitivity demonstrates improved clinical performance
